FDA Greenlights Drugs to Battle Screwworms in Cats and Dogs
Published Date: 12/29/2025
Notice
Summary
The FDA just gave the green light for two new emergency animal drugs to treat nasty New World screwworm infections in dogs, puppies, cats, and kittens. These quick-acting treatments are now officially authorized as of late 2025 to help protect pets from this serious health threat. Pet owners and vets can expect faster access to these lifesaving drugs without extra costs right now.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
EUA for Dog Screwworm Treatment
The FDA issued an Emergency Use Authorization (EUA) to Elanco US Inc. for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs and puppies. This authorization is effective October 24, 2025 and allows emergency use and introduction into interstate commerce under the FD&C Act section 564.
EUA for Cat Screwworm Treatment
The FDA issued an Emergency Use Authorization (EUA) to Elanco US Inc. for Credelio CAT (lotaliner) to treat New World screwworm (NWS) infestations in cats and kittens. This authorization is effective November 21, 2025 and allows emergency use and introduction into interstate commerce under the FD&C Act section 564.
Faster Access to Pet Treatments Now
The notice states that pet owners and veterinarians can expect faster access to these lifesaving drugs for New World screwworm and that this access is available without extra costs right now. The two EUAs became effective October 24, 2025 and November 21, 2025, respectively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
Previous / Next Documents
Previous: 2025-23913 — Carbon and Certain Alloy Steel Wire Rod From China; Determinations
The U.S. government decided to keep special taxes on carbon and certain alloy steel wire rod imported from China because removing them could hurt American steel makers. These taxes help protect U.S. jobs and businesses from unfair competition. This decision was finalized at the end of 2025 and means importers will keep paying these extra fees for now.
Next: 2025-23952 — Sunshine Act Meetings
The National Council on Disability is holding a two-day meeting in January 2026, both in Orlando and online, to discuss important issues like youth in nursing homes, disaster experiences, and accessible transportation. This meeting affects people with disabilities, especially in Florida, and aims to improve policies and services. No new costs are mentioned, but the event invites public input and shares updates on ongoing projects.